|
|
Research on Lipodystrophy & Other Metabolic Complications
2008
- Tesamorelin for Fat Accumulation (May/June 2008)
52-week effects and safety of tesamorelin (growth hormone releasing factor) in HIV patients with fat accumulation.
In Positively Aware, from Test Positive Aware Network
- U.S. Study Confirms Long-Term Use of AZT, d4T Result in Lipoatrophy (May 27, 2008)
From aidsmap.com
- Taking a Half Dose of d4T Doesn't Reduce Fat Loss (April 16, 2008)
From aidsmap.com
- Connection Found Between Belly Fat and Dementia (March 27, 2008)
From Project Inform
- Genetics May Protect Some From Lipoatrophy (March 18, 2008)
From aidsmap.com
- Study Looks at How Much Fat a Person Can Lose Without Noticing It (February 11, 2008)
In 15th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- HIV/HCV-Coinfected Patients Appear More Likely Than HIV-Monoinfected Patients to Develop Insulin Resistance After Initiating HAART (February 5, 2008)
From The Body PRO
- Body Fat Changes Becoming Less Common as HIVers Use Fat-Friendlier Meds, Study Finds (January 23, 2008)
In HIV Medicine
2007
- Study Suggests Drug Can Reduce Abdominal Fat in HIVers Taking HIV Meds (October 31, 2007)
In aidsmap.com
- ICAAC: Gains in Limb Fat and CD4 Counts Continue Three Years After Switching From d4T to Tenofovir (September 21, 2007)
From aidsmap.com
- Increased Fat Consumption Observed in People With HIV With High Cholesterol (August 22, 2007)
From aidsmap.com
- Dietary Intervention When Starting HAART Prevents the Increase in Lipids Independently of Drug Regimen: A Randomized Trial (July 25, 2007)
From International AIDS Society
- Switching to Thymidine-Sparing Regimens Successful (July 25, 2007)
Since thymidine-sparing, NRTI-based regimens are associated with fewer instances of lipoatrophy and hyperlipidemia than thymidine-containing, NRTI-based regimens, switching to a thymidine-sparing, fixed-dose combination of NRTIs is feasible and associated with no unexpected adverse events, including those affecting renal function and bone mineral density. Graeme Moyle, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
- The Role of Nucleoside Analogs in the Development of Insulin Resistance (July 24, 2007)
NRTIs to date have been thought to contribute to insulin resistance mainly via induction of lipoatrophy. The authors of this paper put forth another potential mechanism based on their findings: that is, zidovudine (AZT, Retrovir)-mediated mitochondrial toxicity in skeletal muscle, adipocytes and hepatocytes. Margaret Hoffman-Terry, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
- Protein Buildup May Be Linked to Fat Gain in HIVers on Protease Inhibitors, Researchers Say (July 18, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Study Shows TH9507 May Help Treat HIV-Related Fat Gain (Summer 2007)
To read PDF, click here
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Testosterone Levels, Fat Free Mass, Increases Differ According to HIV Drugs Taken (June 4, 2007)
From aidsmap.com
- Canadian Study Finds Bio-Alcamid Safe, Effective for Facial Lipoatrophy (May 22, 2007)
From aidsmap.com
- Study May Disprove Link Between HIV/Hep C Coinfection and Some Metabolic Problems (May 21, 2007)
A pair of new U.S. studies appears to contradict long-held concerns that HIV/hepatitis C-coinfected people have a higher risk of diabetes and lipoatrophy (fat loss).
From aidsmap.com
- Study Casts Doubt on Glitazones as Lipoatrophy Treatment (May 8, 2007)
From AIDSMeds.com
- Metabolic Complications: A CROI Round-Up (February 28, 2007)
Includes an analysis of research examining lopinavir/ritonavir vs. efavirenz, the use of growth hormone releasing factor to treat fat gain, the link between cardiovascular disease and HIV treatment, the use of ezetimibe (a choleserol-reducing agent) and the latest on bone health in HIV-infected patients.
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- An Interview With Steven Grinspoon, M.D. (February 26, 2007)
Dr. Grinspoon, presented the results of a large trial looking at the effects of a growth hormone releasing factor analog on HIV-associated abdominal fat accumulation .
2006
- FDA Approves Radiesse for Treating Facial Lipoatrophy (December 29, 2006)
From U.S. Food and Drug Administration
- Waist Size No Different in HIV-Infected Men on HAART Than in HIV-Uninfected Men (November 15, 2006)
From aidsmap.com
- Comparing the Effects of Rosiglitazone, Pravastatin, Recombinant Human Growth Hormone and Combinations Thereof on HIV-Associated Lipodystrophy (September 30, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Recombinant Human Growth Hormone Produces Pronounced and Durable Reductions in Visceral Adipose Tissue (September 30, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Metabolic Complications of HIV Therapy (September 2006)
To read PDF, click here
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Initiation of HAART May Increase Free Testosterone Levels and Fat-Free Mass (August 17, 2006)
In XVI International AIDS Conference
- Metabolic Complications at the XVI International AIDS Conference: Part 1 -- An Overview of New Data (August 17, 2006)
In XVI International AIDS Conference
- Metabolic Complications at the XVI International AIDS Conference: Part 2 -- Lipids (August 17, 2006)
In XVI International AIDS Conference
- Interventions for Fat Changes: New Research on Glitazones, Metformin and Testosterone (February 8, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- PI-Based Therapy Does Not Increase Glucose Intolerance, Gestational Diabetes in Pregnant, HIV-Infected Women (February 6, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
- HIV JournalView: Metabolic Complications and HAART: Some New Answers and Many More Questions (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
2005
- Benefit of Rosiglitazone or Metformin for Lipodystrophy Still Unclear (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Switching Due to Lipoatrophy: Tenofovir Bests Abacavir in Tolerability, Lipid Profile (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Protease Inhibitors Not Associated With Fat Gain; Some Antiretrovirals Can Cause Fat Loss, Study Says (November 3, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From The Body PRO
- Moderate Weight Loss Increasingly Common for HIVers on HAART (September 1, 2005)
Wasting syndrome may be on the decline, but moderate weight loss -- of 5% or more -- has increased steadily since 1995, and appears unrelated to lipodystrophy.
From aidsmap.com
- Abacavir Is Not Associated With the Metabolic Changes Seen in Patients Treated With Stavudine (February 24, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Five Ways to Tackle Toxicity (or the Ant, the Spider, and the Bee): 6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (January 2005)
To read PDF, click here
In IAPAC Monthly, from International Association of Physicians in AIDS Care
2004
- Fiber May Help Prevent Lipodystrophy (September 20, 2004)
Weight-bearing exercise and less smoking is also found to reduce the chances that men with HIV will develop fat around their waists.
To read PDF, click here
From PositiveWords
- HIV JournalView: Exogenous Growth Hormone, an Expensive (and Questionable) Fat Accumulation Treatment (September 2004)
From The Body PRO
- HIV JournalView: Using Suction-Assisted Lipectomy to Treat Buffalo Hump (September 2004)
From The Body PRO
- Metabolic Complications of HIV and Its Therapies (July 16, 2004)
A detailed overview of recent research.
In The XV International AIDS Conference
- A HAART Regimen With Lower Metabolic Effect: Nevirapine Plus Non-Thymidine Analog NRTIs (July 14, 2004)
In The XV International AIDS Conference, from The Body PRO
- Kidney Fat Could Be a Predictor of Lipodystrophy (July 6, 2004)
Researchers use ultrasound to gauge the likelihood a patient will develop lipodystrophy after starting HAART, or whether a treatment switch will improve existing lipodystrophy.
From aidsmap.com
- Vitamins and Exercise May Help HIV-Related Metabolic Disorders (June 19, 2004)
In The Advocate
- Vitamins, Exercise May Help Metabolic Disorders (June 16, 2004)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Lipid-Lowering Drug Helps Triglyceride Levels in HIVers With Lipodystrophy (June 2004)
A daily dose of fenofibrate is found to lower abnormally high triglyceride levels in HIV-positive people with lipodystrophy, without causing any severe side effects.
In American Journal of Medical Science
- Rosiglitazone Reduces Lipoatrophy, Hyperinsulinemia in HIV-Infected Patients, Study Finds (May 19, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Canadian Company Reports Promising Lipodystrophy Treatment (April 19, 2004)
ThGRF has been found to reduce abdominal fat in HIV-infected patients without adversely affecting blood-glucose levels.
From aidsmap.com
- Can Atazanavir Reverse Body Fat Changes? (April 8, 2004)
Anecdotal evidence recently reported in the journal AIDS suggests that atazanavir (Reyataz) may treat lipodystrophy.
From aidsmap.com
- Diabetes Drug and Exercise Help Reduce Heart Disease Risk and Improve Body Shape in HAART Patients (March 12, 2004)
From aidsmap.com
- Complications of Antiretroviral Therapies and HIV (March 2004)
An examination of diabetes, kidney disease, bone problems and hypertension research from the February Retrovirus conference.
In Hopkins HIV Report
- CROI 2004 Recap: Metabolic Complications (March 2004)
David Wohl, M.D., reviews research highlights from the 11th Conference on Retroviruses and Opportunistic Infections.
In HEPP Report, from Brown Medical School
- Lipodystrophy & Metabolic Complications (March 2004)
A summary of several research highlights on metabolic complications from February's 11th Conference on Retroviruses and Opportunistic Infections.
In Hopkins HIV Report
- An Overview of the Metabolic Complications of HIV/HAART (February 11, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- No Lipodystrophy Yet Seen With Regimens Including Enfuvirtide (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Unboosted Atazanavir Better on Insulin Sensitivity Compared to Lopinavir/Ritonavir (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
2003
- Fiber-, Protein-, Calorie-Rich Diet Appears to Protect Against Central Fat Gain in Men (December 11, 2003)
From aidsmap.com
- High-Fiber Diet in HIV-Positive Men Is Associated With Lower Risk of Developing Fat Deposition (November 2003)
Abstract of a study in the American Journal of Clinical Nutrition.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- New Form of Liposuction Able to Reduce Buffalo Hump -- At Least in the Short Term (October 20, 2003)
A combination of liposuction and ultrasound is found to make buffalo humps smaller, but for half of the study patients the hump eventually grew back fully.
From aidsmap.com
- Sublime Versus Simple Side Effect Stories (or, Forget the Adiponectin, Just Stop Smoking) -- 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (October 2003)
To read PDF, click here
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Dyslipidemia: Change to Tenofovir? (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Women Get More Lipodystrophy Than Men, Says Italian Study (September 10, 2003)
In this large study, women on HAART were found to be at a greater risk for developing body fat changes than men -- although men generally seemed to LOSE fat more often than women.
From aidsmap.com
- Antioxidants Have Little Benefit in People With Lipoatrophy (August 29, 2003)
A combination of vitamin E, vitamin C and N-acetylcysteine has positive and negative health results.
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Little Lipodystrophy Seen With Either Atazanavir or Efavirenz (July 16, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- FRAM Study Finds a Lack of Association Between Lipoatrophy and Central Fat Gain (July 15, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- HIV-Positive Teenagers With Lipodystrophy Have Lower Growth Hormone Secretion (July 1, 2003)
Researchers conducting a small study believe they've found the first link between lipodystrophy and lack of growth hormone in children on HAART.
From aidsmap.com
- New Drug Being Studied for Lipodystrophy (June 23, 2003)
The promise of TH9507, a peptide that stimulates growth hormone production.
From Canadian AIDS Treatment Information Exchange
- Diabetes Risk Triples in Women on PIs (April 24, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Increased Lipodystrophy Is Associated With Increased Exposure to Highly Active Antiretroviral Therapy in HIV-Infected Children (April 15, 2003)
In Journal of AIDS
- Emory Researchers Identify Link Between Lipid Abnormalities and AIDS Therapy (April 4, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Bezafibrate Improves Glucose Uptake and Endothelial Function in HIV Patient (March 28, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Metabolic and Morphologic Complications in HIV Disease: What's New (March 11, 2003)
A review of recent findings on insulin resistance, body fat changes and related problems.
In The PRN Notebook
- Retrovirus 2003: Management of Metabolic Complications (February 14, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Improvements in Body Fat and Mitochondrial DNA Levels Are Accompanied by Decreased Adipose Tissue Cell Apoptosis After Replacement of Stavudine Therapy With Either Abacavir or Zidovudine (February 13, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Lipid Changes in a Randomized Comparative Trial of First-Line Antiretroviral Therapy With Regimens Containing Either Nevirapine Alone, Efavirenz Alone or Both Drugs Combined, Together With Stavudine and Lamivudine (2NN Study) (February 13, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Nutrition and Exercise to Manage Lipodystrophy (January 2003)
Research from the 2002 International AIDS Conference.
In Project Inform Perspective, from Project Inform
- Protease Inhibitors and Atherosclerosis (January/February 2003)
In TAGline, from Treatment Action Group
- Report From the 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (January 2003)
In Hopkins HIV Report
- Segmental BIA: Can We Measure Lipodystrophy? (December 2002/January 2003)
Emerging data reported at the ninth annual ANSA Conference.
In Survival News, from AIDS Survival Project
|
|
